Group 1 - The article highlights the positive outlook for the innovative drug sector, particularly focusing on the investment value of the Hang Seng Biotechnology ETF (520933) [1] - Arrowhead, a leader in small nucleic acids, released positive clinical data for two weight-loss pipelines targeting INHBE (ARO-INHBE) and ALK7 (ARO-ALK7), reinforcing the potential of small nucleic acid drugs in the weight-loss field [1] - The core driving factor for the current innovative drug market is the breakthrough competitiveness of Chinese pharmaceutical companies on a global scale, with increasing recognition of their R&D capabilities by multinational corporations [1] Group 2 - The Hang Seng Biotechnology Index focuses on innovative drugs, showcasing three main advantages: gathering leading companies, scarcity of futures liquidity, and high elasticity & Sharpe ratio [1] - Investors looking to conveniently participate in the core leaders of the innovative drug sector are encouraged to consider the Hang Seng Biotechnology ETF (520933) for a streamlined investment approach [1]
看好创新药板块性机会，关注恒生生物科技ETF国泰（520933）投资价值
Mei Ri Jing Ji Xin Wen·2026-01-15 04:02